Dr. Chandarlapaty on Role of the PI3K Pathway in Breast Cancer

Sarat Chandarlapaty, MD, PhD
Published: Monday, Aug 29, 2016


Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of the PI3K pathway in patients with metastatic breast cancer.

Although there has not been an agent yet developed that successfully targets PI3K, Chandalapty says the pathway still has a significant role.

PI3K mutations may be less frequent than AKT mutations in patients with metastatic breast cancer, he adds. However, developing a drug that specifically targets PI3K-mutant tumors may help researchers in achieving activity in a difficult-to-treat population.
SELECTED
LANGUAGE

Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of the PI3K pathway in patients with metastatic breast cancer.

Although there has not been an agent yet developed that successfully targets PI3K, Chandalapty says the pathway still has a significant role.

PI3K mutations may be less frequent than AKT mutations in patients with metastatic breast cancer, he adds. However, developing a drug that specifically targets PI3K-mutant tumors may help researchers in achieving activity in a difficult-to-treat population.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x